Authors' conclusions
There is currently no rigorous RCT evidence available regarding the effects of NPWT compared with alternatives for the treatment of pressure ulcers. High uncertainty remains about the potential benefits or harms, or both, of using this treatment for pressure ulcer management.
P L A I N L A N G U A G E S U M M A R Y
Negative pressure wound therapy for treating pressure ulcers
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are areas of injury to the skin, the tissue that lies underneath, or both. Pressure ulcers can be painful, may become infected, and affect people's quality of life. People at risk of developing pressure ulcers include those with spinal cord injuries, and those who are immobile or who have limited mobility.
In 2004 the total annual cost of treating pressure ulcers in the UK was estimated as being GBP 1.4 to 2.1 billion, which was equivalent to 4% of the total National Health Service expenditure. People with pressure ulcers stay longer when admitted to hospital, and this increases hospital costs. Figures from the USA for 2006 suggest that half a million hospital stays had 'pressure ulcer' noted as a diagnosis; the total hospital costs of these stays was USD 11 billion.
There is a wide variety of treatment options available for pressure ulcers, such as dressings, creams, redistribution of pressure, and negative pressure wound therapy (NPWT). NPWT is a technology that is used widely and is promoted for use on wounds, including pressure ulcers. In NPWT a machine which exerts carefully controlled suction (negative pressure) is attached to a wound dressing that covers the pressure ulcer. This sucks any wound and tissue fluid away from the treated area into a canister. The researchers tried to discover whether NPWT works well as a treatment for pressure ulcers.
What we found
We searched the medical literature up to May 2015 for robust medical studies (randomised controlled studies) that compared NPWT with other treatments for pressure ulcers. We identified four studies involving a total of 149 participants. Two studies compared NPWT with dressings, one compared NPWT with a series of topical treatments and one study compared it with what was described only as 'moist wound healing'. The trials were small, and poorly described, of fairly short or unclear duration, and contained little in the way of useful data.
As a result of the limited amount of research evidence available, we were not able to draw any conclusions regarding the potential value (or harm) of NPWT as a treatment for pressure ulcers. More, better quality research is needed if this is an important and relevant question for decision makers.
This plain language summary is up-to-date as of May 2015.
B A C K G R O U N D Description of the condition
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both. They often occur in areas with a bony prominence such as the sacrum (base of the spine) and heel (Vanderwee 2007) , and are caused by external forces such as pressure, or shear, or a combination of both (EPUAP-NPUAP 2009 ). Populations at risk of pressure ulceration include those with spinal cord injuries (Gefen 2014), and those immobilised or with limited mobility such as elderly people and people with acute or chronic conditions that might limit movement or bodily sensation, or both (Allman 1997; Berlowitz 1990; Berlowitz 1997; Bergstrom 1998; Brandeis 1994) . Incontinence can also increase risk of ulceration by producing a detrimental environment for the skin (Brandeis 1994) . Impaired nutritional status may also increase risk (Allman 1997; Donini 2005) , however, there is currently limited evidence for the effectiveness of nutritional intake interventions for preventing or treating pressure ulcers (Langer 2003; Smith 2013) . Mobility produces relief from pressure within the body through regular, often sub-conscious, shifts in positions when sitting or lying. These movements, triggered by a reduction in oxygen levels at pressure points and possible discomfort, distribute pressure from contact at the surface, thus reducing the compression of soft tissue against bone (Gebhardt 2002) . Populations with limited autonomous movement or conditions that dull body sensation, or both (as described above), are at risk of failing to achieve adequate pressure relief. Prolonged exposure of an area of the body to pressure or compression can interrupt the local blood circulation and trigger a cascade of biochemical changes that may lead to tissue damage and ulceration. Immobility can also lead to increased damage from shear and friction, for example, when people are pulled into position in chairs and beds. Pressure ulcers vary in severity. One of the most widely recognised systems for categorising pressure ulcers is that of the National Pressure Ulcer Advisory Panel which is summarised below (NPUAP 2009) . Category/Stage I -non-blanchable erythema: "Intact skin with non-blanchable redness of a localized area usually over a bony prominence. Darkly pigmented skin may not have visible blanching; its colour may differ from the surrounding area. The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. Category I may be difficult to detect in individuals with dark skin tones. May indicate "at risk" persons." Category/Stage II -partial thickness: "Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum-filled or sero-sanguinous filled blister. Presents as a shiny or dry shallow ulcer without slough or bruising (bruising indicates deep tissue injury). This category should not be used to describe skin tears, tape burns, incontinence associated dermatitis, maceration or excoriation." Category/Stage III -full thickness skin loss: "Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. Slough may be present but does not obscure the depth of tissue loss. May include undermining and tunnelling. In the UK, national pressure ulcer data are collected across community and acute settings -although data collection is not yet universal -as part of the National Health Service (NHS) Safety Thermometer initiative (Power 2012). In January 2014, 5% of patients across these settings were estimated to have a pressure ulcer (National Safety Thermometer Data 2014). We note that all of the prevalence figures quoted above are for populations currently receiving medical care. The point prevalence of pressure ulceration in the total adult population was recently estimated using a cross-sectional survey undertaken in Leeds, UK. Of the total adult population of 751,485 the point prevalence of pressure ulceration per 1000 was 0.31 (Hall 2014) . UK pressure ulcer prevalence estimates specifically for community settings have reported rates of 0.77 per 1000 adults in a UK urban area (Stevenson 2013) . Pressure ulcers have a large impact on those affected; the ulcers can be painful, and may become seriously infected or malodorous. It has been shown that -after adjustment for age, sex and co-morbidities -people with pressure ulcers have a lower health-related quality of life than those without pressure ulcers (Essex 2009). The financial cost of treating ulcers in the UK was recently estimated as being between GBP 1214 for a stage I ulcer, to GBP 14,108 for a stage IV ulcer (Dealey 2012). In 2004 the total annual cost of treating pressure ulcers in the UK was estimated as being GBP 1.4 to 2.1 billion, which was equivalent to 4% of the total NHS expenditure (Bennett 2004). Pressure ulcers have been shown to increase length of hospital stay, readmission and mortality rates (Lyder 2012), and to add considerably to the cost of an episode of hospital care (Chan 2013). Figures from the USA suggest that for half a million hospital stays in 2006 'pressure ulcer' was noted as a diagnosis; for adults, the total hospital costs of these stays was USD 11 billion (Russo 2008) . Costs to the Australian healthcare system for treating pressure ulceration have been estimated at AUD 285 million per annum (Graves 2005).
Description of the intervention
Negative pressure wound therapy (NPWT) is a technology that is currently used widely in wound care and is promoted for use on complex wounds (e.g. Guy 2012). NPWT involves the application of a wound dressing through which a negative pressure (or vacuum) is applied, often with the wound and tissue fluid drawn away from the area being collected in a canister. The intervention was developed in the 1990s, and the uptake of NPWT in the healthcare systems of developed countries has been dramatic. A US Department of Health report estimated that between 2001 and 2007, Medicare payments for NPWT pumps and associated equipment increased from USD 24 million to USD 164 million (an increase of almost 600%; Department of Health and Human Services 2009). Initially only one NPWT manufacturer supplied NPWT machines (the VAC system: Kinetic Concepts Inc (KCI), San Antonio, Texas), however, as the NPWT market has grown, a number of different commercial NPWT systems have been developed, with machines becoming smaller and more portable. Indeed, the most recent introduction to the market is a single use, or 'disposable', negative pressure product. Ad hoc, non-commercial, negative pressure devices are also used, especially in resource-poor settings. These devices tend to use simple wound dressings, such as gauze, or transparent occlusive (non-permeable) dressings, with negative pressure generated in hospital by vacuum suction pumps. A number of different healthcare professionals prescribe and apply NPWT, and it is now used both in secondary and primary (community) care, particularly following the introduction of ambulatory systems, and prophylactically, to prevent surgical site infection. Whilst the NPWT systems outlined above differ in a number of respects -such as type of pressure (constant or cyclical) applied to the wound, the material in contact with the surface of the wound and also the type of dressing used -the principle of applying a negative pressure to the wound in a closed environment is the same for all products.
How the intervention might work
NPWT can collect high volumes of wound exudate, so may reduce the frequency of dressing changes, and subsequent exposure of the wound to the environment. This collection of exudate ostensibly assists in the management of anatomically-challenging wounds, keeps wounds clean, and reduces wound odour. Manufacturers, however, also suggest that the application of negative pressure (suction) to the wound actually promotes healing by drawing together the wound edges, increasing perfusion (oxygenated blood in the tissues) and removing infectious material and exudate (Kinetic Concepts Inc 2012). Potential negative consequences of NPWT include wound maceration (softening due to exposure to liquid), and retention of dressing materials that may cause wound infection, as well as other injuries (FDA 2011) . NPWT devices are usually worn continually by patients during treatment. They can interfere with mobility, and, anecdotally, are often noisy, which prevents some patients from sleeping.
Why it is important to do this review
Given its widespread use, it is important to assess the current evidence regarding the clinical and cost effectiveness of NPWT. Previous review work has found little evidence about the effects of NPWT on severe pressure ulcers (Soares 2013). UK pressure ulcer guidelines (for both prevention and management) advise "Do not routinely offer adults negative pressure wound therapy to treat a pressure ulcer, unless it is necessary to reduce the number of dressing changes (for example, in a wound with a large amount of exudate)" (NICE 2014) . The guidelines also highlight the need for further research, noting that there would be "benefits to patients and the NHS in establishing whether negative pressure wound therapy improves the healing of pressure ulcers." The production of a robust and updated systematic review can contribute to this aim by identifying, appraising and synthesising the evidence base to inform decision makers and possibly guide future research.
O B J E C T I V E S
To assess the effects of negative pressure wound therapy for treating pressure ulcers in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled trials (RCTs), including cluster RCTs, irrespective of the language of report. Cross-over trials would be included only if they reported outcome data at end of the first treatment period, before crossover. Studies using quasi-randomisation were excluded.
Types of participants
We included studies recruiting adults with a pressure ulcer (category II or above), managed in any care setting. We excluded trials of participants with category I ulcers. We accepted study authors' definitions of what they classed as category II or above, unless it was clear that wounds with unbroken skin were included. Studies that recruited participants with category II or higher pressure ulcers alongside people with other types of wounds were included if the results for people with relevant pressure ulcers were presented separately (or were available from the study authors).
Types of interventions
The primary intervention of interest was negative pressure wound therapy (NPWT), both commercial and non-commercial treatments. We included any RCT in which the NPWT during the treatment period was the only systematic difference between treatment groups. We anticipated likely comparisons would include use of NPWT during the care pathway compared with no use of NPWT, or comparison of different types/brands of NPWT used during the care pathway.
Types of outcome measures
We list primary and secondary outcomes below. If a study was apparently eligible (i.e. correct study design, population and intervention/comparator), but did not report a listed outcome, we contacted the study authors where possible to establish whether an outcome of interest here was measured, but not reported. We report outcome measures at the latest time point available for a study (assumed to be length of follow-up if not specified) and the time point specified in the methods as being of primary interest (if this was different from latest time point available). For all outcomes we categorise outcomes from:
• under a week to eight weeks as short-term;
• over eight weeks to 26 weeks as medium-term; and • over 26 weeks as long-term.
Primary outcomes
The primary outcomes for this review were complete wound healing and adverse events.
Complete wound healing
For this review we regarded the following as providing the most relevant and rigorous measures of wound healing:
• time to complete wound healing: we recorded whether this had been correctly analysed using censored data and with adjustment for prognostic covariates such as baseline size;
• the proportion of ulcers healed (frequency of complete healing).
Where both the outcomes above were reported, we present all data in a summary outcome table for reference. Where equal amounts of information were available, we anticipated focusing on time to healing as the key outcome measure. We accepted authors' definitions of what constituted a healed wound.
Adverse events (generic)
Reported data were extracted on adverse events classed as 'serious adverse events' and 'non-serious adverse events' where a clear methodology for the collection of adverse event data was provided. This methodology needed to make it clear whether events were reported at the participant level or, where multiple events/person were reported, that an appropriate adjustment had been made for data clustering. Individual types of adverse events such as pain or infection that require specific assessment were not extracted under this outcome -rather this is the assessment of any event classed as adverse by the patient and or health professional during the trial.
Secondary outcomes
• Change (and rate of change) in wound size, with adjustment for baseline size: we contacted study authors to request adjusted means when these were not presented. Where change or rate of change in wound size was reported without adjustment for baseline size, we documented use of the outcome in the study, but did not summarize the data in the narrative or use them in any meta-analysis.
• Participant health-related quality of life/health status: measured using a standardised generic questionnaire such as EQ-5D, SF-36, SF-12 or SF-6 or wound-specific questionnaires such as the Cardiff wound impact schedule. We did not include ad hoc measures of quality of life that were not likely to be validated and would not be common to multiple trials.
• Wound infection: as defined by author.
• Mean pain scores: (including pain at dressing change) we included this information only where the data were reported as either a presence or absence of pain, or as a continuous outcome using a validated scale such as a visual analogue scale (VAS).
• Resource use: including measurements of resource use such as number of dressing changes, nurse visits, length of hospital stay, re-admission and re-operation/intervention.
• Costs: any costs applied to resource use.
• Wound recurrence: as defined by study author.
Search methods for identification of studies Electronic searches
In May 2015 we searched the following electronic databases to retrieve reports of potentially relevant RCTs.
• 
Searching other resources
We contacted corresponding authors and the manufacturers and distributors of NPWT. We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials as well as relevant systematic reviews, meta-analyses, and health technology assessment reports.
Data collection and analysis

Selection of studies
Two review authors independently assessed the titles and abstracts of the citations retrieved by the searches for relevance. After this initial assessment, we obtained full text copies of all studies felt to be potentially relevant. Two review authors independently checked the full papers for eligibility; disagreements were resolved by discussion and, where required, the input of a third review author. We recorded all reasons for the exclusion of studies for which we had obtained full copies of the text. We have completed a PRISMA flowchart to summarize this process ( Figure 1 ; Liberati 2009).
Where required we would obtain all relevant publications when studies were reported more than once. Whilst the study was included only once in the review, all reports were examined to ensure the maximal extraction of relevant data.
Data extraction and management
We extracted and summarize details of the eligible studies. Two review authors extracted data independently and resolved disagreements by discussion, drawing on a third review author where required. Where data were missing from reports, we attempted to contact the study authors to obtain this information. Had a study with more than two intervention arms been included, we would have extracted only those data from intervention and control groups that met the eligibility criteria. We extracted the following data where possible, by treatment group, for the pre-specified interventions and outcomes in this review. Outcome data were collected for relevant time points as described in Types of outcome measures.
• • Outcome data for primary and secondary outcomes (by group)
• Duration of follow-up • Number of withdrawals (by group)
• Publication status of study; and • Source of funding for trial.
Assessment of risk of bias in included studies
Two review authors independently assessed included studies using the Cochrane Collaboration tool for assessing risk of bias (Higgins 2011a). This tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting and other issues. In this review we recorded issues with unit of analysis, for example where a cluster trial has been undertaken but analysed at the individual level in the study report (Appendix 2). We assessed blinding and completeness of outcome data for each of the review outcomes separately. We note that, since wound healing is a subjective outcome, it can be at high risk of measurement bias when outcome assessment is not blinded. We present our assessment of risk of bias using two 'Risk of bias' summary figures; one is a summary of bias for each item across all studies, and the second shows a cross-tabulation of each trial by all of the 'Risk of bias' items. We planned to class studies with an assessment of high risk of bias for the randomisation sequence domain or the allocation concealment domain, or both, to be at a high risk of selection bias; those at a high risk of bias for the blinded outcome assessment domain (for a specified outcome) as being at a high risk of detection bias, and those with a high risk of bias for the intention-to-treatment domain as being at a high risk of attrition bias (for a specified outcome). For trials using cluster randomisation, we assessed the risk of bias considering recruitment bias, baseline imbalance, loss of clusters, incorrect analysis and comparability with individually randomised trials (Higgins 2011b; Appendix 3).
Measures of treatment effect
For dichotomous outcomes we calculated the risk ratio (RR) with 95% confidence intervals (CI). For continuously distributed outcome data we used the mean difference (MD) with 95% CIs, for trials that used the same assessment scale. If trials used different assessment scales, we used the standardised mean difference (SMD) with 95% CIs. We only considered mean or median time to healing without survival analysis as a valid outcome if reports specified that all wounds healed (i.e. if the trial authors regarded time to healing as a continuous measure, as there is no censoring). Time-to-event data (e.g. time-to-complete wound healing), were reported as hazard ratios (HR) where possible in accordance with the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2011). If studies reporting time-toevent data (e.g. time to healing) did not report a hazard ratio, then, where feasible, we planned to estimate this using other reported outcomes, such as the numbers of events, through the application of available statistical methods (Parmar 1998).
Unit of analysis issues
Where studies randomised at the participant level and measured outcomes at the wound level, for example for wound healing, and the number of wounds appeared to be equal to the number of participants, we treated the participant as the unit of analysis. We had anticipated a possible unit of analysis issue if individual participants with multiple wounds were randomised, the allocated treatment used on the multiple wounds per participant (or perhaps only on some participants) and then data were presented and analysed by wound not person. This is a type of clustered data and presents a unit of analysis error which inflates precision. In cases where included studies contained some or all clustered data we planned to report this alongside whether data had been (incorrectly) treated as independent. We recorded this as part of the risk of bias assessment. We did not plan to undertake further calculation to adjust for clustering. We also planned to record when randomisation and allocation had been undertaken at the wound level -that is a split-site or splitbody design, and assess whether the correct paired analysis had been undertaken in the study, issues would have been recorded in the risk of bias section.
Dealing with missing data
It is common to have data missing from trial reports. Excluding participants post-randomisation from the analysis, or ignoring those participants who are lost to follow-up compromises the randomisation, and potentially introduces bias into the trial. Where there were data missing that we thought should be included in the analyses, we contacted the relevant study authors to enquire whether these data were available.
Where data for 'proportion of wounds healed' remained missing, we assumed that if randomised participants were not included in an analysis, their wound did not heal (i.e. they would be considered in the denominator but not the numerator).
In a time-to-healing analysis using survival analysis methods, dropouts should be accounted for as censored data, so we took no action regarding missing data. For continuous variables, for example length of hospital stay, and for all secondary outcomes, we presented the data available from the study reports/study authors and did not plan to impute missing data. We calculated missing measures of variance where possible. If calculation was not possible, we contacted the study authors. Where these measures of variation were not available the study was excluded from any relevant meta-analyses that were conducted.
Assessment of heterogeneity
Assessment of heterogeneity can be a complex, multi-faceted process. Where assessment of heterogeneity was required we firstly considered clinical and methodological heterogeneity: that is the degree to which the included studies varied in terms of participant, intervention, outcome and characteristics such as length of follow-up. This assessment of clinical and methodological heterogeneity was supplemented by information regarding statistical heterogeneity -assessed using the Chi² test (a significance level of P < 0.10 was considered to indicate statistically significant heterogeneity) in conjunction with the I² measure (Higgins 2003 
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. Publication bias is one of a number of possible causes of 'small study effects', that is, a tendency for estimates of the intervention effect to be more beneficial in smaller RCTs. Funnel plots allow a visual assessment of whether small study effects may be present in a metaanalysis. A funnel plot is a simple scatter plot of the intervention effect estimates from individual RCTs against some measure of each trial's size or precision (Sterne 2011). We planned to present funnel plots for meta-analyses comprising 10 RCTs or more using RevMan 5.3 (RevMan 2014).
Data synthesis
Details of included studies were combined in a narrative review according to type of comparator, possibly by location of/type of wound and then by outcomes by time period. Where appropriate and required clinical and methodological heterogeneity were considered and we anticipated pooling data when studies appeared appropriately similar in terms of wound type, intervention type, duration of follow-up and outcome type, thus synthesis is considered viable. Our standard approach for meta-analytical analyses was to employ a random-effects model. Our preference for the more conservative random effects model is because statistical assessments can miss potentially important between-study heterogeneity in small samples, (Kontopantelis 2012). A fixed effect analyses was only planned when, in the judgement of the review authors, there was minimal clinical heterogeneity and this was supported by an X 2 value is estimated to be statistically non-significant and an I 2 of 0% (Kontopantelis 2013). In all other circumstances a random-effects model will be adopted. If relevant where clinical heterogeneity was thought to be acceptable or of interest we planned to meta-analyse even when statistical heterogeneity is high -attempting to interpret the causes behind this heterogeneity -use of meta-regression for that purpose would also be considered (Thompson 1999; Thompson 2002) . Data were presented using forest plots where possible. For dichotomous outcomes present the summary estimate as a risk ratio (RR) with 95% CI. Where continuous outcomes were measured in the same way across studies, we planned to present a pooled mean difference (MD) with 95% CI; we planned to pool mean difference (MD) estimates where studies measured the same outcome using different methods. For time-to-event data, we planned to plot (and, if appropriate, pool) estimates of hazard ratios and 95% CIs as presented in the study reports using the generic inverse variance method in RevMan 5.3. Where time to healing was analysed as a continuous measure but it was not clear if all wounds healed, use of the outcome in the study will be documented but data would not be summarised or used in any meta-analysis. Pooled estimates of treatment effect would be obtained using Cochrane RevMan software (version 5.3) (RevMan 2014).
'Summary of findings' tables
We planned to present the main results of the review in 'Summary of findings' tables. These tables are used to present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (Schunemann 2011a). 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach. The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision (or imprecision) of effect estimates and risk of publication bias (Schunemann 2011b).
• time to complete wound healing where analysed using appropriate survival analysis methods;
• proportion of wounds completely healing during the trial period;
• adverse events.
Where data were not pooled it was decided to conduct the GRADE assessment for each comparison and present this narratively within the results section without the presentation of separate summary of finding tables.
Subgroup analysis and investigation of heterogeneity
Had there been sufficient included trials and data, we had planned to assess potential heterogeneity across the following areas where there was evidence of between-trial heterogeneity. We envisaged conducting subgroup analyses for:
• category of ulcer;
• features of negative pressure system and/or vacuum cycle protocol used;
• duration of NPWT treatment.
• methodological features of studies (allocation adequately concealed versus not reported or inadequate) and type of randomisation (truly randomised with adequate method of generating the randomisation sequence versus not reported).
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies
Results of the search
We screened 75 citations obtained from the electronic search. We obtained full texts for a further seven studies following their identification from bibliographic searches. In total we obtained (or attempted to obtain) 22 references, relating to 19 studies, as fulltexts. (Figure 1) . We included four studies in the review (Ashby 2012; de Laat 2011; Ford 2002; Niezgoda 2004) ; we excluded 12 studies and three are awaiting assessment as we have been unable to obtain the full texts for two (Pruksapong 2011; Yu 2012) , and one study did not have obvious outcome data, but the graphs presented require more exploration for the data on change in wound volume at two weeks (Wanner 2003) . • a choice of three standard dressing types in Ashby 2012, follow-up time 24 weeks: "Devices were used in accordance with the manufacturer's guidance. The duration of treatment was determined by the nurse treating the patient and also the patient, in accordance with current practice."
• a wet-to-moist dressing with a sodium hypochlorite 0.25% solution in de Laat 2011, follow-up time six weeks: "The fluid connection system was changed at least once a week. Negative pressure mode of 125 mm Hg."
• the Healthpoint system (which uses three gel treatments) in Ford 2002, follow-up time unclear: "NPWT dressings were changed Mondays, Wednesdays, and Fridays (manufacturer recommends dressing changes every 48 hours)."
• and to moist wound healing with no further definition in Niezgoda 2004, follow-up time 6 weeks: no further details.
Ashby 2012 was described as a pilot study. Niezgoda 2004 was presented as an interim analysis; no further data were available from the study authors, who confirmed that the study had not been published in full.
Excluded studies
Twelve studies were excluded from the review for the following reasons:
• not a randomised controlled trial (two studies; Mullner 1997; Tauro 2007);
• NPWT was not the only systematic difference between study groups (two studies; Wagstaff 2014; Zhang 2012);
• no outcomes relevant to this review reported or obtained from study authors to date (one study; Wild 2008);
• study population had mixed wounds and data on the • we were unable to obtain any further information regarding the study (no abstract or publication; one study; Greer 1999).
Risk of bias in included studies
See Figure 
Allocation
We deemed Ashby 2012 to be at low risk of selection bias. The randomisation sequence for the study was computer-generated and allocation was undertaken via telephone by an operator who was not directly associated with the trial. The remaining three studies were classed as being at an unclear risk of selection bias as they reported limited information about the methods employed.
Blinding
We deemed two studies to be at a low risk of detection bias for wound healing as they undertook blinded outcome assessment ( Ashby 2012; Ford 2002). It was noted in de Laat 2011 that blinded outcome assessment was not possible for healing outcomes, so we classed this study as being at a high risk of detection bias. Niezgoda 2004 did not report any information about blinding being used in the study, and we classed it as being at an unclear risk of detection bias.
Incomplete outcome data
We classed two studies as being at low risk of attrition bias (Ashby 2012; de Laat 2011), and two studies at high risk of attrition bias 
Selective reporting
We classed all the studies as being at low risk of reporting bias except for Niezgoda 2004, which we classed as being at unclear risk due to the limited information available about it.
Other potential sources of bias
We classed one study as being at high risk of bias due to unit of analysis issues (Ford 2002). In the de Laat 2011 study participants could also have more than one ulcer -it was not clear how these data were analysed and whether there were unit of analyses issues, so we classed the study as being at unclear risk of bias for this domain.
Effects of interventions
See Table 1 for a summary of included studies and outcome data.
Comparison 1: NPWT compared with standard dressings; short-term follow-up (one study, 12 participants)
One study with 6 weeks follow-up compared NPWT with conventional dressings in people with spinal cord injury and pressure ulcers (de Laat 2011). The study was deemed to be at high risk of detection bias.
Primary outcomes
The de Laat 2011 study did not report on complete wound healing or adverse events.
Secondary outcome: change in ulcer size
There was no evidence of a difference between groups in the number of pressure ulcers considered to have a 50% (or more) reduction in wound volume at the end of the six-week follow-up with 83% (5/6) participants recorded as reaching this end point in each group (RR 1.00, 95% CI 0.60 to 1.66; Analysis 1.1). The study reported a median time to reach a 50% (or greater) reduction in wound volume of two weeks (inter-quartile range (IQR) 1 to 2) in the NPWT-treated group compared with three weeks (IQR 3 to 4) in the dressing-treated group. We have not analysed the data further here.
GRADE assessment: Very low quality evidence due to risk of bias, indirectness of the outcome (complete healing is preferable) and imprecision.
Other secondary outcomes
The de Laat 2011 study did not report on: health-related quality of life; wound infection; pain; resource use; cost; or wound recurrence.
Summary: NPWT compared with standard dressings; shortterm follow-up (one study, 12 participants)
Limited data from one study with 12 participants report no evidence of a difference in numbers achieving a 50% reduction in wound volume over 6 weeks of follow-up. Using the GRADE approach this was judged as very low quality evidence due to risk of bias, indirectness of the outcome and imprecision
Comparison 2: NPWT compared with standard dressings therapy; medium-term follow-up (one study, 12 participants)
One study compared NPWT with standard dressings with 24 weeks follow-up (Ashby 2012). The study was a pilot study which explicitly stated that it was not designed or powered to detect treatment effects. We judged the study as being at low risk of bias for all domains. The study compared NPWT with standard dressings (alginate, foam or hydrofibre -the choice of these being left to health professionals).
Primary outcome: proportion of wounds healed
There was no evidence of a difference in the number of wounds healed in the NPWT group (17%, 1/6) and the dressing group (0%, 0/6): RR 3.00, 95% CI 0.15 to 61.74; Analysis 2.1). The study was not powered to detect a difference in wound healing, and there was such huge imprecision around the estimates that neither a positive nor negative effect of NPWT can be ruled out.GRADE assessment: Very low quality evidence due to imprecision.
Primary outcome: adverse events
There was no evidence of a difference in the number of participants with adverse events in the NPWTgroup (83%, 4/6) and the dressing group (67%, 4/6): RR: 1.25, 95% CI 0.64 to 2.44; Analysis 2.2). Again the study was underpowered and findings were imprecise largely as it was not designed to assess relative treatment effects. GRADE assessment: Very low quality evidence due to imprecision.
Secondary outcomes
The Ashby 2012 study did not report on: change in ulcer size, health-related quality of life, wound infection, pain, resource use, cost, or wound recurrence. It did report on the number of trial treatment visits that were made, but we did not extract these data as the duration of treatments differed (Table 1) .
Summary: NPWT compared with standard dressings therapy; medium-term follow-up (one study, 12 participants)
Limited evidence from a study with 12 participants reported no evidence of a difference between groups for ulcer healing or adverse events. The study was underpowered and its finds are far from conclusive. GRADE assessment: Very low quality evidence due to imprecision.
Comparison 3: NPWT compared with moist wound healing; short-term follow-up (one study, 97 participants)
One study compared NPWT with 'moist wound healing', but provided few details about the comparator intervention (Niezgoda 2004) . The only information available came from a conference abstract; no further published information was available. The study was presented as an interim analysis at a point when recruitment and follow-up of recruited participants was not complete. We considered it to be at a high risk of attrition bias.
Primary outcomes
The Niezgoda 2004 study did not report on complete wound healing or adverse events.
Secondary outcome: change in ulcer size
The Niezgoda 2004 study reported only unadjusted data for change in ulcer size (Table 1) which we did not consider further as per our methods.
Secondary outcome: resource use
The mean cost of care (including materials, labour, debridements and length of stay) in the NPWT-treated group was USD 130 compared with USD 132 in the moist wound healing group. No information about the variation around these estimates was presented and the data are not analysed further here.
Other secondary outcomes
The Niezgoda 2004 study did not report on: health-related quality of life, wound infection, pain, cost, or wound recurrence.
Summary: NPWT compared with moist wound healing; short-term follow-up (one study, 97 participants)
The only study to compare NPWT with moist wound healing provided very limited information from which it is not possible to draw conclusions regarding the effectiveness of NPWT with this alternative pressure ulcer treatment regime. There was not enough data to conduct a GRADE assessment but the lack of data meant we consider this very low quality evidence.
Comparison 4: NPWT compared with the Healthpoint system (one study, 28 participants)
One study compared NPWT with the Healthpoint system (Ford 2002) . The Healthpoint System consists of three gel products: Accuzyme®, Iodosorb®, and Panafil®. The study reports that of the choice of three treatments available -participants whose wounds showed substantial exudate received Iodosorb® or Iodoflex®; those patients whose ulcers were clean and granulating received Panafil®. Accuzyme® was not used.We considered the study to be at high risk of attrition bias; it also had unit of analysis issues. It should be noted that the study was reported to be an interim analysis, and that the length of follow-up was unclear.
Primary outcome data: proportion of ulcers healed
The study reported that two ulcers healed in each study arm. However whilst the number of participants for the study were reported (n = 28), the number in each arm was not, and there were 41 wounds in the study. It was not clear whether one or two participants healed in each group. Due to these unit of analysis issues, we have not analysed the data further here.
Primary outcome data: adverse events
The Ford 2002 study did not report adverse events clearly (Table  1) .
Secondary outcomes
The Ford 2002 study did not report on change in ulcer size, healthrelated quality of life, wound infection, pain, resource use, cost, or wound recurrence.
Summary: NPWT compared with the Healthpoint system (1 study, 28 participants)
Very few data were available from comparison of NPWT with the Healthpoint system. We are unable to make any conclusions regarding the effectiveness of NPWT compared with the Healthpoint system. There was not enough data to conduct a GRADE assessment but the lack of data meant we consider this very low quality evidence.
D I S C U S S I O N
Summary of main results
We included a total of four studies in this review (Ashby 2012; de Laat 2011; Ford 2002; Niezgoda 2004) . Only Ashby 2012, which was a pilot/feasibility study, reported primary outcome data on both the proportion of wounds healed and adverse events that we report fully in the review. Whilst there was no evidence of a difference between NPWT and standard dressings for these outcomes, the study was hugely underpowered having only 12 participants and so its estimates were very imprecise and inconclusive. The fact that only one participant healed during the 24-week follow-up period highlights the need for adequate follow-up in studies that evaluate treatments for severe pressure ulcers. We classed the three remaining studies as being at high risk of bias for at least one risk of bias domain (de Laat 2011; Ford 2002; Niezgoda 2004) ; they also had short or unclear follow-up times.
One of these studies that also had 12 participants (de Laat 2011), reported no evidence of a difference in the number of wounds achieving a 50% (or greater) reduction in wound volume over a six-week follow-up period. This was a surrogate outcome and the comparison was again underpowered and imprecise. Overall there is low quality and inconclusive evidence regarding the clinical effectiveness of NPWT as a treatment for pressure ulcers.
Quality of the evidence
RCTs need to be adequately powered so that they are able to detect treatment effects of a specified size, should they exist. This means that sample size calculations should be used to help estimate the number of people recruited to a trial. Additionally, trials should have adequate an follow-up period so that there is enough time in which important outcome events, such as complete wound healing, can occur. The trials included in this review were all small and their follow-up periods were also generally short, and in one case was not reported clearly. This results in a limited evidence base: further problems in quality also stem from the limited outcomes reported in the trials. Wound healing or preparation for closure surgery, as well as adverse events, are potentially important outcomes. Such outcomes should be collected rigorously using a clear methodology. On this occasion there was a limited number of studies that could be included in this review; those studies presented limited outcome data with estimates that were imprecise and had wide confidence intervals. Rigorous RCTs in wound care are feasible -they must follow good practice conduct and reporting guidelines, for example CON-SORT (Schulz 2010). Key areas of good practice are the robust generation of a randomisation sequence, for example, a computergenerated one; robust allocation concealment, for example the use of a telephone randomisation service; and use of blinded outcome assessment where possible. All this information should be stated clearly in the study report, as trial authors should anticipate the inclusion of their trials in systematic reviews. Additionally, studies should report clearly how they planned to collect adverse event data and how this process was standardised for both treatment arms. In terms of analysis, where possible, data from all participants should be included -that is an intention-to-treat analysis should be conducted -and measures of variation such as the standard deviation or standard error should be presented around measures where appropriate. Steps should be taken while a trial is being conducted to prevent the occurrence of missing data as far as is possible.
Potential biases in the review process
The review considered as much evidence as it was possible to obtain, including studies that were not published in English-language journals. It is possible that there may be unpublished data that we have not been able to access and there is a potential for publication bias, however, this is likely to be a limited issue in this review.
Agreements and disagreements with other studies or reviews
NICE guidelines currently state, "Do not routinely offer adults negative pressure wound therapy to treat a pressure ulcer, unless it is necessary to reduce the number of dressing changes (for example, in a wound with a large amount of exudate)" (NICE 2014). The review underpinning this NICE guidance is based is similar to our review, although we included one additional RCT. Our review did not find or report any cost-effectiveness data reported as part of the RCT data. However, two published cost-effectiveness modelling studies (one conducted as part of the NICE guidelines; NICE 2014) draw on available data, and emphasise again the uncertainty around the clinical and cost-effectiveness of NPWT as a treatment for pressure ulcers.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This comprehensive review of current randomised controlled trial evidence has highlighted the current uncertainty regarding the effectiveness of negative pressure wound therapy (NPWT) as a treatment for pressure ulcers. Given the current uncertainties, when choosing between alternative treatment options for pressure ulcers, practitioners may elect to consider characteristics such as costs and symptom management properties.
Implications for research
Where it is a priority for patients, carers and health professionals, further research to evaluate the clinical and cost effectiveness of NPWT as a treatment for pressure ulcers is warranted. Large and robust randomised controlled trials would probably be the most appropriate study design.
When trials are conducted, good practice guidelines must be followed in their design, implementation and reporting. Further reviews are being conducted to synthesise evidence regarding the effect of other treatments for pressure ulcers. It would then be useful to conduct further evidence synthesis (overviews of reviews, network meta-analysis or both) to aid decision-making about the choice of treatments for pressure ulcers across all treatment options.
A C K N O W L E D G E M E N T S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Ashby 2012
Methods 2-arm RCT Conducted in home and hospital settings in 1 geographical location in the UK Duration of follow-up was a maximum of 24 weeks Favours dressings Favours NPWT 3. Blinding -was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.
High risk of bias
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following.
• Insufficient information available to permit a judgement of low or high risk of bias.
• The study did not address this outcome.
Were incomplete outcome data adequately addressed? Low risk of bias
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes was not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.
• 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
